window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 30, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

targeted protein degradation

  • Biotech,Clinical Trials,Drug discovery,Funding,Oncology,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development,Technology and platforms

    Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline

    Neomorph has closed a $100 million Series B financing to [...]

    April 18, 2026
  • Biotech,Drug discovery,Healthcare leadership,Movers & Shakers,Research & Development,Startups and innovations,Technology and platforms

    Proxygen appoints Chiara Conti as chief scientific officer to support move into clinical-stage development

    Proxygen has appointed Chiara Conti as chief scientific officer, as [...]

    April 2, 2026
  • Biotech,Funding,Immunology,Oncology,Research & Development

    Laigo Bio raises €17m seed funding to advance oncology pipeline

    Laigo Bio has completed a €17 million seed financing round [...]

    March 23, 2026
  • Biologics & Biosimilars,Biotech,Drug Development,Pharmaceuticals and therapeutics,Technology and platforms

    Argobio-backed Enodia raises €20.7 million seed to advance small-molecule protein degradation platform

    Argobio Studio has announced the successful seed financing of Enodia [...]

    January 12, 2026
  • Cell & Gene Therapy,Neurosciences,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development

    TRIMTECH Therapeutics establishes scientific advisory board to advance targeted protein degradation

    TRIMTECH Therapeutics, a biotech developing small molecule therapeutics that selectively [...]

    September 9, 2025
  • Clinical Development,Drug Delivery & Formulation,Drug Development,Movers & Shakers,Oncology,Precision medicine

    PhoreMost appoints Pfizer drug discovery veteran Dr Adam Gilbert to scientific advisory board

    Appointment strengthens expertise in targeted protein degradation as company advances [...]

    July 28, 2025
  • Biologics & Biosimilars,Drug Development,Oncology,Research & Development,Technology and platforms

    PhoreMost unveils breakthrough platform to rationalise molecular glue drug discovery

    High-throughput GlueSEEKER platform expands druggable space by identifying novel induced [...]

    July 22, 2025
  • Movers & Shakers

    PhoreMost brings in biotech major players with $30B+ in deal history

    Company says appointments of Barbara Duncan and Stephen Dilly will [...]

    May 12, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ARTCLINE completes enrolment in septic shock trial for ARTICE therapy
    Categories: Biotech, Cell & Gene Therapy, Clinical Development, Clinical Trials, Infectious Diseases, Pharmaceuticals and therapeutics
  • SGD Pharma highlights GLP-1 demand, supply chain pressure and sustainability focus at DCAT Week
    Categories: CDMOs & Manufacturing, Healthcare leadership, Market Access & Commercialization, Pharmaceuticals and therapeutics, Supply Chain & Logistics
  • ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development
    Categories: Drug Delivery & Formulation, Drug Development, Oncology, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top